Your browser doesn't support javascript.
loading
Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.
Davies, Katherine; Buczkowski, Hubert; Welch, Stephen R; Green, Nicole; Mawer, Damian; Woodford, Neil; Roberts, Allen D G; Nixon, Peter J; Seymour, David W; Killip, Marian J.
Affiliation
  • Davies K; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
  • Buczkowski H; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
  • Welch SR; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
  • Green N; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
  • Mawer D; York Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
  • Woodford N; National Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, NW9 5EQ, London, UK.
  • Roberts ADG; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
  • Nixon PJ; York Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
  • Seymour DW; York Hospitals NHS Foundation Trust, Wigginton Road, York, YO31 8HE, UK.
  • Killip MJ; High Containment Microbiology, NIS Laboratories, National Infection Service, Public Health England, 61 Colindale Avenue, Colindale, London, NW9 5EQ, UK.
J Gen Virol ; 102(4)2021 04.
Article in En | MEDLINE | ID: mdl-33913803
ABSTRACT
Infectious SARS-CoV-2 can be recovered from the oral cavities and saliva of COVID-19 patients with potential implications for disease transmission. Reducing viral load in patient saliva using antiviral mouthwashes may therefore have a role as a control measure in limiting virus spread, particularly in dental settings. Here, the efficacy of SARS-CoV-2 inactivation by seven commercially available mouthwashes with a range of active ingredients were evaluated in vitro. We demonstrate ≥4.1 to ≥5.5 log10 reduction in SARS-CoV-2 titre following a 1 min treatment with commercially available mouthwashes containing 0.01-0.02 % stabilised hypochlorous acid or 0.58 % povidone iodine, and non-specialist mouthwashes with both alcohol-based and alcohol-free formulations designed for home use. In contrast, products containing 1.5 % hydrogen peroxide or 0.2 % chlorhexidine gluconate were ineffective against SARS-CoV-2 in these tests. This study contributes to the growing body of evidence surrounding virucidal efficacy of mouthwashes/oral rinses against SARS-CoV-2, and has important applications in reducing risk associated with aerosol generating procedures in dentistry and potentially for infection control more widely.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Virus Inactivation / SARS-CoV-2 / Mouthwashes Limits: Humans Language: En Journal: J Gen Virol Year: 2021 Type: Article Affiliation country: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Virus Inactivation / SARS-CoV-2 / Mouthwashes Limits: Humans Language: En Journal: J Gen Virol Year: 2021 Type: Article Affiliation country: United kingdom